HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)
ID: 345222Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345222

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-069.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the HEAL Commercialization Readiness Pilot (CRP) Program, aimed at supporting small businesses in advancing pain management technologies. This funding opportunity is specifically designed for small business concerns that have previously received SBIR or STTR Phase II or IIB funding, with the goal of integrating entrepreneurial expertise into their leadership teams to enhance commercialization readiness and attract private investment. The program is particularly significant as it addresses the critical need for innovative, non-addictive pain management solutions in response to the opioid crisis. Eligible applicants can request funding of up to $400,000 over a maximum of two years, with applications due by September 5, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-069.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-069-Full-Announcement.html
    PAR-23-069.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has launched the HEAL Commercialization Readiness Pilot (CRP) Program aimed at advancing small businesses in pain management technologies. This funding opportunity is designed for small business concerns (SBCs) that have received SBIR or STTR Phase II or IIB funding, facilitating the inclusion of entrepreneurial expertise in their leadership teams to attract private investment and form industry partnerships. The program does not accept clinical trial proposals and focuses solely on enhancing commercialization readiness. Eligible applicants can request funding of up to $400,000 over a maximum of two years, with specific due dates for applications. The CRP aims to address the significant gaps in business development capabilities among SBCs, as many lack resources for non-research activities necessary for commercialization. The application process requires detailed plans for hiring business experts, establishing a partnering strategy, and demonstrating readiness for private fundraising. The program reflects NIH's commitment to combatting the opioid crisis by promoting innovative, non-addictive pain management solutions, making it a crucial initiative within the broader HEAL Initiative.
    Similar Opportunities
    HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management," aimed at addressing the national opioid public health crisis. This initiative encourages small businesses to develop innovative, non-addictive therapies and technologies for improved pain management, including new medications, pain-assessment devices, and treatment strategies for chronic pain. The funding available includes up to $275,766 for Phase I and $1,838,436 for Phase II grants, with applications due by April 4, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at developing innovative therapies and technologies for enhanced pain management. This initiative specifically seeks applications from small businesses focused on creating non-addictive pain treatment alternatives, objective pain measurement tools, and new screening methodologies to address the national opioid crisis. With an annual funding projection of up to $8 million for 5-15 awards, eligible applicants must be U.S. small businesses, and the application deadline is set for April 4, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-006.html.
    HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of non-addictive analgesic therapeutics, specifically small molecules and biologics, aimed at treating pain. The initiative seeks to accelerate the optimization and transition of promising therapeutic candidates to Phase I clinical trials, requiring applicants to demonstrate a compelling biological rationale and suitable assays for their projects. This funding is crucial for addressing the needs of over 25 million Americans suffering from chronic pain while providing alternatives to opioids. Approximately $11 million is anticipated for distribution across four awards in FY 2024, with applications due by January 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, which aims to support small business concerns (SBCs) in advancing their previously funded SBIR and STTR Phase II and Phase IIB projects towards commercialization. This funding opportunity provides financial assistance for technical support and late-stage research and development activities that are typically not covered by standard Phase II or Phase IIB grants, excluding clinical trials. Eligible applicants must have active Phase II or Phase IIB awards from participating NIH institutes within the last 36 months, with potential funding reaching up to $1,000,000 per year for a maximum of three years. Interested parties should contact NIH Grants Information at grantsinfo@nih.gov for further inquiries, and note that the application deadline is April 5, 2025.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices," aimed at addressing the opioid epidemic by promoting innovative research into alternative pain management solutions. This initiative seeks interdisciplinary research teams composed of multiple Principal Investigators (PDs/PIs) to explore the mechanisms of action of FDA-approved medical devices designed for pain relief, with the goal of optimizing therapeutic outcomes and enhancing understanding of device-based therapies. With over 25 million Americans suffering from chronic pain, this funding is critical for developing safe and effective pain treatment options that minimize addiction risks. Interested applicants can apply for grants with an award ceiling of $1.5 million, and proposals are due by June 9, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-028.html.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, aimed at providing technical assistance and support for late-stage development of small business concerns (SBCs) engaged in the commercialization of health-related technologies. This funding opportunity encourages SBCs with prior NIH funding to apply for grants that facilitate the transition from research to market, specifically requiring at least one clinical trial as part of the proposed project. The CRP program addresses the funding gap between SBIR/STTR Phase II awards and commercialization, supporting activities such as regulatory assistance, manufacturing, and clinical studies. Interested applicants must submit their proposals by April 5, 2025, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative for the development of clinical-grade diagnostic and therapeutic devices aimed at treating pain and addressing opioid use disorder (OUD). This grant seeks to support the creation of non-addictive device-based technologies, advancing them from early development to preclinical stages suitable for FDA approval, with a focus on demonstrating treatment efficacy through credible neural targets. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, for-profit entities, and tribal governments, with funding available for up to three years and a maximum budget of $750,000 annually. Interested parties should note that the application deadline is June 17, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.